Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Grocery business lifts Cosco income

2018-05-16 bworldonline
COSCO CAPITAL, Inc. reported its net income attributable to equity holders of the parent rose 8% in the first quarter, driven by robust sales of its grocery retail and liquor businesses.
PGCMF PRGLY COSCO PGOLD

5
Puregold: Pace of Lawson expansion was too slow

2018-05-13 bworldonline
PUREGOLD PRICE Club, Inc. chose to divest from the Lawson chain of convenience stores after its Japanese partner failed to deliver on its expansion program.
PGCMF ITOCY SSI ITOCF AYAAY SEVN PHSVY PRGLY PGOLD ALI AYAAF

5
High inflation, TRAIN Law pose risks to Puregold sales growth in 2018

2018-05-08 business.inquirer.net
The Puregold Price Club in General Mariano Alvarez, Cavite, is one of 31 Puregold stores in South Luzon. PHOTO FROM GMACAVITE.COM.
PGCMF PSKXF PHSXY PSE PRGLY PGOLD

5
Puregold drops convenience store

2018-04-27 bworldonline
PUREGOLD Price Club, Inc. has sold its stake in the Lawson chain of convenience stores after accepting its Japanese partner’s offer to buy out its 70% stake in the venture.
PGCMF PSKXF PHSXY PSE PRGLY PGOLD

0
Puregold divests from Lawson brand

2018-04-27 bworldonline
Puregold Price Club, Inc. has divested from the Lawson chain of convenience stores, after accepting its Japanese partner’s offer to buyout its 70% stake in the venture.
PGCMF PRGLY PGOLD

5
Philippine stock woes mount as 2018 losses pass $20-billion mark

2018-04-17 bworldonline
PHILIPPINE stocks, already the world’s worst performers this year, fell to the lowest in almost a year Tuesday, bringing to more than $20 billion the loss in market value for the country’s benchmark index since the start of 2018.
BDOUF BDO PGCMF BDOUY PRGLY PGOLD

5
Philippine Stock Woes Mount as 2018 Losses Pass $20 Billion Mark - Bloomberg

2018-04-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BDOUF BDO PGCMF BDOUY PRGLY PGOLD

6
Puregold earns P5.84B in 2017

2018-04-16 bworldonline
EARNINGS of Puregold Price Club, Inc. grew by 5.7% in 2017, backed by a double-digit increase in sales from its chain of supermarkets across the country.
PGCMF PSKXF PHSXY PSE PRGLY PGOLD

1
Puregold nets P5.8B

2018-04-16 business.inquirer.net
Lucio Co-led retailer Puregold Price Club grew net profit last year by 5.7 percent to P5.84 billion, riding on robust consumer spending in the country by adding new stores and increasing sales out of old stores.
PGCMF PRGLY PGOLD

1
Firms see robust sales despite TRAIN

2018-04-15 bworldonline
FILIPINOS did not hold back on spending despite higher prices of goods in the first quarter of the year, but elevated input costs would continue to put pressure on the profitability of consumer companies.
PGCMF SEVN PHSVY PRGLY COL PGOLD

16
Tech businesses powering Asia-Pacific growth

2018-04-05 bworldonline
London’s venerable Financial Times (FT) recently released its first-ever “FT 1000 High-Growth Companies Asia-Pacific” list — with 26 Filipino firms making the grade, all of which are listed on the Philippine Stock Exchange except for one.
JGSMY CNPF JGS ATI SGI CEBUY TUGS ACR SSI JBFCF MWP PHSXY H2O LNSTY PSE MWIDE CEB AISNY JGSHF CIC PSKXF JBFCY PRGLY PGOLD MBC PGCMF CROWN TECH STI CEBUF SPC JFC PERC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 74624G105